UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/615,262	07/09/2003	Ryuichi Morishita	Q75926	5695
23373 SUGHRUE MI	7590 01/03/2007 ION, PLLC	EXAMINER		
2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037			KELLY, ROBERT M	
			ART UNIT	PAPER NUMBER
			1633	
	· · · · · · · · · · · · · · · · · · ·			·
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MO	NTHS	01/03/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)			
Office Action Summary		10/615,262	MORISHITA ET AL.			
		Examiner	Art Unit			
		Robert M. Kelly	1633			
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status			•			
1)⊠	Responsive to communication(s) filed on <u>03 C</u>	October 2006				
	his action is FINAL . 2b)⊠ This action is non-final.					
, —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
-,_	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
		Expans quayre, root c.b. 11;	· · · · · · · · · · · · · · · · · · ·			
Dispositi	on of Claims	•				
4)🛛	Claim(s) 7-11 is/are pending in the application	1.				
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)□	5) Claim(s) is/are allowed.					
6)⊠	6)⊠ Claim(s) <u>7-11</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)[Claim(s) are subject to restriction and/o	or election requirement.				
Application Papers						
9)	The specification is objected to by the Examino	er.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
The salit of assistation to objected to by the Examiner. Note the attached office Action of John 1 10-102.						
Priority u	ınder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
	e of References Cited (PTO-892)	4) ☐ Interview Summar				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application 6) Other:						

Application/Control Number: 10/615,262

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/3/06 has been entered.

Claims 7-8 and 11 are amended.

Claims 7-11 are presently pending and considered.

Substitute Specification

It is noted that Applicant's amendment to the specification is accepted.

Drawings

In light of the amendments to the specification, the objections to the drawings is withdrawn.

Claim Objections

In light of the amendments to Claim 7, the objections to Claims 7-11 are withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

Art Unit: 1633

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

In light of the amendments, the rejections of Claims 7-11 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, are withdrawn.

Claims 7-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 recites a method to treat insufficient peripheral circulation or peripheral angiostenosis, but only subsequently comprises a step of administration of vector. Without a conclusion, explaining that the HGF is subsequently expressed and causes angiogenesis, thereby treating the disorder, the Artisan would not know how this method is completed. Hence, the metes and bounds of the method are not defined because the claim lacks a commensurate conclusion.

Claims 8-11 are rejected for depending from a rejected base claim without overcoming the lack of clarity in such base claim.

Claim Rejections - 35 USC § 112 - new matter

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1633

In light of Applicant's amendments, the rejections of Claims 7-11 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement, are withdrawn. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Specifically, the claims no longer specifically claim treating a peripherial muscle.

However, the following new matter rejection is applied:

Claims 7-11 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 7-11 are drawn to treating any sufficiency of peripheral circulation/angiostenosis comprising administering intramuscularly at the affected site, a vector.

Applicant's claims now encompass treating any peripheral circulation/angiostenosis, in any organ, by administration of HGF encoding vectors into a muscle at the affected site.

However, while Applicant's specification teaches administration through "appropriate" routes (p. 13) and directly to the objective site (p. 14), the term appropriate route does not provide any demonstration of possession except the art-accepted routes for any specific disease, not any route which works, and the objective site would be understood by the Artisan to mean to the area affected. Applicant's claims, however, when given their broadest reasonable interpretation include treating any tissue, e.g., including liver or brain, etc., and injection into a

Application/Control Number: 10/615,262

Art Unit: 1633

muscle at the site affected. There is no teaching in the specification as to which muscles are considered to be "at" any particular affected site, and the Art does not recognize such terminology. Hence, the Artisan does not know which muscles Applicant is referring to in any particular instance.

Hence, the Artisan would not have understood Applicant to have been in possession of the invention as presently claimed.

Response to Argument - New Matter

Applicant's argument of 10/3/06 has been fully considered but is not found persuasive.

Applicant's argument is deemed to be fully responded to by the argument, above, in the new rejection, inasmuch as it applies to the new rejection under this basis.

Claims free of Prior Art

It is noted that the claims remain free of the prior art.

Conclusion

No Claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Art Unit: 1633

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert M. Kelly, Art Unit 1633, whose telephone number is (571) 272-0729. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert M. Kelly, Ph.D. Examiner, USPTO, AU 1633 Patents Hoteling Program Mailbox 2C70, Remsen Building (571) 272-0729

C/or World